Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Growth 2026-2032
The global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market size is predicted to grow from US$ 583 million in 2025 to US$ 1001 million in 2032; it is expected to grow at a CAGR of 8.2% from 2026 to 2032.
Paroxysmal Nocturnal Hemoglobinuria (PNH) drugs refer to a class of medications used to treat Paroxysmal Nocturnal Hemoglobinuria, a rare, life-threatening blood disorder characterized by the destruction of red blood cells, blood clots, and impaired bone marrow function. These drugs primarily work by inhibiting the complement system, an immune response that, when overactive in PNH patients, leads to the destruction of red blood cells. Treatments like eculizumab and ravulizumab are commonly used PNH drugs, helping to reduce hemolysis (red blood cell breakdown), manage symptoms, and improve patients' quality of life.
CANbridge Pharmaceuticals Inc., Kira Pharmaceuticals, Wuhan Createrna Science and Technology Co., Ltd., NovelMed, Akari Therapeutics, Omeros Corporation and Regeneron Pharmaceuticals are mainly developing complement-targeted drugs and clinical-stage candidate drugs for PNH. None of them have launched commercially available finished PNH drugs so far. Therefore, these enterprises are listed as PNH drug pipeline players and potential market entrants in this report, and shall not be combined with manufacturers of marketed PNH drugs for statistics on current commercial sales volume.
In 2025, global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs production reached approximately 98 K doses, with an average global market price of around US$ 6,100 per dose.
The Paroxysmal Nocturnal Hemoglobinuria (PNH) drugs market is experiencing significant growth, driven by the rising prevalence of the disease and increasing awareness. The market size is expanding, with North America, particularly the U.S., and Europe being the major sales regions due to advanced healthcare infrastructure and higher diagnosis rates. Emerging markets in Asia-Pacific present significant opportunities due to a growing healthcare sector and rising patient awareness. However, challenges such as high treatment costs and limited access to advanced therapies in developing regions persist. Future product development trends focus on improving efficacy, reducing treatment frequency, and introducing cost-effective biosimilars, potentially expanding access to underserved populations.
LP Information, Inc. (LPI) ' newest research report, the ?Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Forecast? looks at past sales and reviews total world Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs sales for 2026 through 2032. With Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs industry.
This Insight Report provides a comprehensive analysis of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market?
What factors are driving Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market opportunities vary by end market size?
How does Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs break out by Type, by Application?
Paroxysmal Nocturnal Hemoglobinuria (PNH) drugs refer to a class of medications used to treat Paroxysmal Nocturnal Hemoglobinuria, a rare, life-threatening blood disorder characterized by the destruction of red blood cells, blood clots, and impaired bone marrow function. These drugs primarily work by inhibiting the complement system, an immune response that, when overactive in PNH patients, leads to the destruction of red blood cells. Treatments like eculizumab and ravulizumab are commonly used PNH drugs, helping to reduce hemolysis (red blood cell breakdown), manage symptoms, and improve patients' quality of life.
CANbridge Pharmaceuticals Inc., Kira Pharmaceuticals, Wuhan Createrna Science and Technology Co., Ltd., NovelMed, Akari Therapeutics, Omeros Corporation and Regeneron Pharmaceuticals are mainly developing complement-targeted drugs and clinical-stage candidate drugs for PNH. None of them have launched commercially available finished PNH drugs so far. Therefore, these enterprises are listed as PNH drug pipeline players and potential market entrants in this report, and shall not be combined with manufacturers of marketed PNH drugs for statistics on current commercial sales volume.
In 2025, global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs production reached approximately 98 K doses, with an average global market price of around US$ 6,100 per dose.
The Paroxysmal Nocturnal Hemoglobinuria (PNH) drugs market is experiencing significant growth, driven by the rising prevalence of the disease and increasing awareness. The market size is expanding, with North America, particularly the U.S., and Europe being the major sales regions due to advanced healthcare infrastructure and higher diagnosis rates. Emerging markets in Asia-Pacific present significant opportunities due to a growing healthcare sector and rising patient awareness. However, challenges such as high treatment costs and limited access to advanced therapies in developing regions persist. Future product development trends focus on improving efficacy, reducing treatment frequency, and introducing cost-effective biosimilars, potentially expanding access to underserved populations.
LP Information, Inc. (LPI) ' newest research report, the ?Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Industry Forecast? looks at past sales and reviews total world Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs sales in 2025, providing a comprehensive analysis by region and market sector of projected Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs sales for 2026 through 2032. With Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs industry.
This Insight Report provides a comprehensive analysis of the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs.
This report presents a comprehensive overview, market shares, and growth opportunities of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Oral Drugs
- Injectable Drugs
- C5 Inhibitors
- C3 Inhibitors
- Other
- Short-Acting: < 2 Weeks
- Medium-Acting: 2?8 Weeks
- Long-Acting: > 8 Weeks
- Pharmaceutical and Biotechnology Companies
- Clinical
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AstraZeneca
- Novartis
- Apellis Pharmaceuticals
- Roche
- Amgen
- Chugai Pharmaceutical
- Sobi
- Samsung Bioepis
- Teva Pharmaceutical Industries
- CANbridge Pharmaceuticals Inc.
- Kira Pharmaceuticals
- Wuhan Createrna Science and Technology Co., Ltd.
- NovelMed
- Akari Therapeutics
- Omeros Corporation
- Regeneron Pharmaceuticals
What is the 10-year outlook for the global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market?
What factors are driving Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs market opportunities vary by end market size?
How does Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs by Country/Region, 2021, 2025 & 2032
2.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Segment by Type
2.2.1 Oral Drugs
2.2.2 Injectable Drugs
2.2.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type
2.2.3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Type (2021-2026)
2.2.3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Type (2021-2026)
2.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Segment by Complement Target
2.3.1 C5 Inhibitors
2.3.2 C3 Inhibitors
2.3.3 Other
2.3.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Complement Target
2.3.4.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Complement Target (2021-2026)
2.3.4.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue and Market Share by Complement Target (2021-2026)
2.3.4.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Complement Target (2021-2026)
2.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Segment by Duration of Action
2.4.1 Short-Acting: < 2 Weeks
2.4.2 Medium-Acting: 2?8 Weeks
2.4.3 Long-Acting: > 8 Weeks
2.4.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Duration of Action
2.4.4.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Duration of Action (2021-2026)
2.4.4.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue and Market Share by Duration of Action (2021-2026)
2.4.4.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Duration of Action (2021-2026)
2.5 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Segment by Application
2.5.1 Pharmaceutical and Biotechnology Companies
2.5.2 Clinical
2.5.3 Others
2.5.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application
2.5.4.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Market Share by Application (2021-2026)
2.5.4.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Breakdown Data by Company
3.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Sales by Company (2021-2026)
3.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Company (2021-2026)
3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Company (2021-2026)
3.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Company (2021-2026)
3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Company
3.4 Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Location Distribution
3.4.2 Players Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Growth
4.4 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Growth
4.5 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Growth
4.6 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Growth
5 AMERICAS
5.1 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country
5.1.1 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021-2026)
5.1.2 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (2021-2026)
5.2 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021-2026)
5.3 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region
6.1.1 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region (2021-2026)
6.1.2 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Region (2021-2026)
6.2 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021-2026)
6.3 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs by Country
7.1.1 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021-2026)
7.1.2 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (2021-2026)
7.2 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021-2026)
7.3 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs by Country
8.1.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
10.3 Manufacturing Process Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
10.4 Industry Chain Structure of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Distributors
11.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Customer
12 WORLD FORECAST REVIEW FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) DRUGS BY GEOGRAPHIC REGION
12.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size Forecast by Region
12.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Forecast by Region (2027-2032)
12.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Forecast by Type (2027-2032)
12.7 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.1.3 AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.2.3 Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Apellis Pharmaceuticals
13.3.1 Apellis Pharmaceuticals Company Information
13.3.2 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.3.3 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Apellis Pharmaceuticals Main Business Overview
13.3.5 Apellis Pharmaceuticals Latest Developments
13.4 Roche
13.4.1 Roche Company Information
13.4.2 Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.4.3 Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Roche Main Business Overview
13.4.5 Roche Latest Developments
13.5 Amgen
13.5.1 Amgen Company Information
13.5.2 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.5.3 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Amgen Main Business Overview
13.5.5 Amgen Latest Developments
13.6 Chugai Pharmaceutical
13.6.1 Chugai Pharmaceutical Company Information
13.6.2 Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.6.3 Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Chugai Pharmaceutical Main Business Overview
13.6.5 Chugai Pharmaceutical Latest Developments
13.7 Sobi
13.7.1 Sobi Company Information
13.7.2 Sobi Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.7.3 Sobi Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Sobi Main Business Overview
13.7.5 Sobi Latest Developments
13.8 Samsung Bioepis
13.8.1 Samsung Bioepis Company Information
13.8.2 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.8.3 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Samsung Bioepis Main Business Overview
13.8.5 Samsung Bioepis Latest Developments
13.9 Teva Pharmaceutical Industries
13.9.1 Teva Pharmaceutical Industries Company Information
13.9.2 Teva Pharmaceutical Industries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.9.3 Teva Pharmaceutical Industries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Teva Pharmaceutical Industries Main Business Overview
13.9.5 Teva Pharmaceutical Industries Latest Developments
13.10 CANbridge Pharmaceuticals Inc.
13.10.1 CANbridge Pharmaceuticals Inc. Company Information
13.10.2 CANbridge Pharmaceuticals Inc. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.10.3 CANbridge Pharmaceuticals Inc. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 CANbridge Pharmaceuticals Inc. Main Business Overview
13.10.5 CANbridge Pharmaceuticals Inc. Latest Developments
13.11 Kira Pharmaceuticals
13.11.1 Kira Pharmaceuticals Company Information
13.11.2 Kira Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.11.3 Kira Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Kira Pharmaceuticals Main Business Overview
13.11.5 Kira Pharmaceuticals Latest Developments
13.12 Wuhan Createrna Science and Technology Co., Ltd.
13.12.1 Wuhan Createrna Science and Technology Co., Ltd. Company Information
13.12.2 Wuhan Createrna Science and Technology Co., Ltd. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.12.3 Wuhan Createrna Science and Technology Co., Ltd. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Wuhan Createrna Science and Technology Co., Ltd. Main Business Overview
13.12.5 Wuhan Createrna Science and Technology Co., Ltd. Latest Developments
13.13 NovelMed
13.13.1 NovelMed Company Information
13.13.2 NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.13.3 NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 NovelMed Main Business Overview
13.13.5 NovelMed Latest Developments
13.14 Akari Therapeutics
13.14.1 Akari Therapeutics Company Information
13.14.2 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.14.3 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Akari Therapeutics Main Business Overview
13.14.5 Akari Therapeutics Latest Developments
13.15 Omeros Corporation
13.15.1 Omeros Corporation Company Information
13.15.2 Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.15.3 Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Omeros Corporation Main Business Overview
13.15.5 Omeros Corporation Latest Developments
13.16 Regeneron Pharmaceuticals
13.16.1 Regeneron Pharmaceuticals Company Information
13.16.2 Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.16.3 Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Regeneron Pharmaceuticals Main Business Overview
13.16.5 Regeneron Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs by Country/Region, 2021, 2025 & 2032
2.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Segment by Type
2.2.1 Oral Drugs
2.2.2 Injectable Drugs
2.2.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type
2.2.3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Type (2021-2026)
2.2.3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Type (2021-2026)
2.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Segment by Complement Target
2.3.1 C5 Inhibitors
2.3.2 C3 Inhibitors
2.3.3 Other
2.3.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Complement Target
2.3.4.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Complement Target (2021-2026)
2.3.4.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue and Market Share by Complement Target (2021-2026)
2.3.4.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Complement Target (2021-2026)
2.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Segment by Duration of Action
2.4.1 Short-Acting: < 2 Weeks
2.4.2 Medium-Acting: 2?8 Weeks
2.4.3 Long-Acting: > 8 Weeks
2.4.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Duration of Action
2.4.4.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Duration of Action (2021-2026)
2.4.4.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue and Market Share by Duration of Action (2021-2026)
2.4.4.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Duration of Action (2021-2026)
2.5 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Segment by Application
2.5.1 Pharmaceutical and Biotechnology Companies
2.5.2 Clinical
2.5.3 Others
2.5.4 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application
2.5.4.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Market Share by Application (2021-2026)
2.5.4.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Breakdown Data by Company
3.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Sales by Company (2021-2026)
3.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Company (2021-2026)
3.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Revenue by Company (2021-2026)
3.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Company (2021-2026)
3.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Company (2021-2026)
3.3 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Company
3.4 Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Location Distribution
3.4.2 Players Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) DRUGS BY GEOGRAPHIC REGION
4.1 World Historic Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size by Geographic Region (2021-2026)
4.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size by Country/Region (2021-2026)
4.2.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Sales by Country/Region (2021-2026)
4.2.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Revenue by Country/Region (2021-2026)
4.3 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Growth
4.4 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Growth
4.5 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Growth
4.6 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Growth
5 AMERICAS
5.1 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country
5.1.1 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021-2026)
5.1.2 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (2021-2026)
5.2 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021-2026)
5.3 Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region
6.1.1 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region (2021-2026)
6.1.2 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Region (2021-2026)
6.2 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021-2026)
6.3 APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs by Country
7.1.1 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021-2026)
7.1.2 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (2021-2026)
7.2 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021-2026)
7.3 Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs by Country
8.1.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021-2026)
8.1.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (2021-2026)
8.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021-2026)
8.3 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
10.3 Manufacturing Process Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
10.4 Industry Chain Structure of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Distributors
11.3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Customer
12 WORLD FORECAST REVIEW FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) DRUGS BY GEOGRAPHIC REGION
12.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market Size Forecast by Region
12.1.1 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Forecast by Region (2027-2032)
12.1.2 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Forecast by Type (2027-2032)
12.7 Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 AstraZeneca
13.1.1 AstraZeneca Company Information
13.1.2 AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.1.3 AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 AstraZeneca Main Business Overview
13.1.5 AstraZeneca Latest Developments
13.2 Novartis
13.2.1 Novartis Company Information
13.2.2 Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.2.3 Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Novartis Main Business Overview
13.2.5 Novartis Latest Developments
13.3 Apellis Pharmaceuticals
13.3.1 Apellis Pharmaceuticals Company Information
13.3.2 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.3.3 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Apellis Pharmaceuticals Main Business Overview
13.3.5 Apellis Pharmaceuticals Latest Developments
13.4 Roche
13.4.1 Roche Company Information
13.4.2 Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.4.3 Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Roche Main Business Overview
13.4.5 Roche Latest Developments
13.5 Amgen
13.5.1 Amgen Company Information
13.5.2 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.5.3 Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Amgen Main Business Overview
13.5.5 Amgen Latest Developments
13.6 Chugai Pharmaceutical
13.6.1 Chugai Pharmaceutical Company Information
13.6.2 Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.6.3 Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Chugai Pharmaceutical Main Business Overview
13.6.5 Chugai Pharmaceutical Latest Developments
13.7 Sobi
13.7.1 Sobi Company Information
13.7.2 Sobi Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.7.3 Sobi Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Sobi Main Business Overview
13.7.5 Sobi Latest Developments
13.8 Samsung Bioepis
13.8.1 Samsung Bioepis Company Information
13.8.2 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.8.3 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Samsung Bioepis Main Business Overview
13.8.5 Samsung Bioepis Latest Developments
13.9 Teva Pharmaceutical Industries
13.9.1 Teva Pharmaceutical Industries Company Information
13.9.2 Teva Pharmaceutical Industries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.9.3 Teva Pharmaceutical Industries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Teva Pharmaceutical Industries Main Business Overview
13.9.5 Teva Pharmaceutical Industries Latest Developments
13.10 CANbridge Pharmaceuticals Inc.
13.10.1 CANbridge Pharmaceuticals Inc. Company Information
13.10.2 CANbridge Pharmaceuticals Inc. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.10.3 CANbridge Pharmaceuticals Inc. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 CANbridge Pharmaceuticals Inc. Main Business Overview
13.10.5 CANbridge Pharmaceuticals Inc. Latest Developments
13.11 Kira Pharmaceuticals
13.11.1 Kira Pharmaceuticals Company Information
13.11.2 Kira Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.11.3 Kira Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Kira Pharmaceuticals Main Business Overview
13.11.5 Kira Pharmaceuticals Latest Developments
13.12 Wuhan Createrna Science and Technology Co., Ltd.
13.12.1 Wuhan Createrna Science and Technology Co., Ltd. Company Information
13.12.2 Wuhan Createrna Science and Technology Co., Ltd. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.12.3 Wuhan Createrna Science and Technology Co., Ltd. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Wuhan Createrna Science and Technology Co., Ltd. Main Business Overview
13.12.5 Wuhan Createrna Science and Technology Co., Ltd. Latest Developments
13.13 NovelMed
13.13.1 NovelMed Company Information
13.13.2 NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.13.3 NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 NovelMed Main Business Overview
13.13.5 NovelMed Latest Developments
13.14 Akari Therapeutics
13.14.1 Akari Therapeutics Company Information
13.14.2 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.14.3 Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Akari Therapeutics Main Business Overview
13.14.5 Akari Therapeutics Latest Developments
13.15 Omeros Corporation
13.15.1 Omeros Corporation Company Information
13.15.2 Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.15.3 Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Omeros Corporation Main Business Overview
13.15.5 Omeros Corporation Latest Developments
13.16 Regeneron Pharmaceuticals
13.16.1 Regeneron Pharmaceuticals Company Information
13.16.2 Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
13.16.3 Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Regeneron Pharmaceuticals Main Business Overview
13.16.5 Regeneron Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Oral Drugs
Table 4. Major Players of Injectable Drugs
Table 5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021-2026) & (K Doses)
Table 6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Type (2021-2026)
Table 7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Type (2021-2026) & ($ million)
Table 8. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Type (2021-2026)
Table 9. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Type (2021-2026) & (US$/Dose)
Table 10. Major Players of C5 Inhibitors
Table 11. Major Players of C3 Inhibitors
Table 12. Major Players of Other
Table 13. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Complement Target (2021-2026) & (K Doses)
Table 14. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Complement Target (2021-2026)
Table 15. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Complement Target (2021-2026) & ($ million)
Table 16. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Complement Target (2021-2026)
Table 17. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Complement Target (2021-2026) & (US$/Dose)
Table 18. Major Players of Short-Acting: < 2 Weeks
Table 19. Major Players of Medium-Acting: 2?8 Weeks
Table 20. Major Players of Long-Acting: > 8 Weeks
Table 21. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Duration of Action (2021-2026) & (K Doses)
Table 22. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Duration of Action (2021-2026)
Table 23. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Duration of Action (2021-2026) & ($ million)
Table 24. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Duration of Action (2021-2026)
Table 25. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Duration of Action (2021-2026) & (US$/Dose)
Table 26. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale by Application (2021-2026) & (K Doses)
Table 27. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Market Share by Application (2021-2026)
Table 28. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Application (2021-2026) & ($ million)
Table 29. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Application (2021-2026)
Table 30. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Application (2021-2026) & (US$/Dose)
Table 31. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Company (2021-2026) & (K Doses)
Table 32. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Company (2021-2026)
Table 33. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Company (2021-2026) & ($ millions)
Table 34. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Company (2021-2026)
Table 35. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Company (2021-2026) & (US$/Dose)
Table 36. Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Producing Area Distribution and Sales Area
Table 37. Players Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Products Offered
Table 38. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 39. New Products and Potential Entrants
Table 40. Market M&A Activity & Strategy
Table 41. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Geographic Region (2021-2026) & (K Doses)
Table 42. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share Geographic Region (2021-2026)
Table 43. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 44. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 45. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country/Region (2021-2026) & (K Doses)
Table 46. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country/Region (2021-2026)
Table 47. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 48. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Country/Region (2021-2026)
Table 49. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021-2026) & (K Doses)
Table 50. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country (2021-2026)
Table 51. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (2021-2026) & ($ millions)
Table 52. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021-2026) & (K Doses)
Table 53. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2021-2026) & (K Doses)
Table 54. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region (2021-2026) & (K Doses)
Table 55. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Region (2021-2026)
Table 56. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Region (2021-2026) & ($ millions)
Table 57. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021-2026) & (K Doses)
Table 58. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2021-2026) & (K Doses)
Table 59. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021-2026) & (K Doses)
Table 60. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (2021-2026) & ($ millions)
Table 61. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021-2026) & (K Doses)
Table 62. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2021-2026) & (K Doses)
Table 63. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021-2026) & (K Doses)
Table 64. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Country (2021-2026)
Table 65. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021-2026) & (K Doses)
Table 66. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2021-2026) & (K Doses)
Table 67. Key Market Drivers & Growth Opportunities of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
Table 68. Key Market Challenges & Risks of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
Table 69. Key Industry Trends of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
Table 70. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Distributors List
Table 73. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Customer List
Table 74. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Forecast by Region (2027-2032) & (K Doses)
Table 75. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 76. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Forecast by Country (2027-2032) & (K Doses)
Table 77. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Forecast by Region (2027-2032) & (K Doses)
Table 79. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 80. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Forecast by Country (2027-2032) & (K Doses)
Table 81. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Forecast by Country (2027-2032) & (K Doses)
Table 83. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Forecast by Type (2027-2032) & (K Doses)
Table 85. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 86. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Forecast by Application (2027-2032) & (K Doses)
Table 87. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 88. AstraZeneca Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 90. AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 91. AstraZeneca Main Business
Table 92. AstraZeneca Latest Developments
Table 93. Novartis Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 95. Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 96. Novartis Main Business
Table 97. Novartis Latest Developments
Table 98. Apellis Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 100. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 101. Apellis Pharmaceuticals Main Business
Table 102. Apellis Pharmaceuticals Latest Developments
Table 103. Roche Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 105. Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 106. Roche Main Business
Table 107. Roche Latest Developments
Table 108. Amgen Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 110. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 111. Amgen Main Business
Table 112. Amgen Latest Developments
Table 113. Chugai Pharmaceutical Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 115. Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 116. Chugai Pharmaceutical Main Business
Table 117. Chugai Pharmaceutical Latest Developments
Table 118. Sobi Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Sobi Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 120. Sobi Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 121. Sobi Main Business
Table 122. Sobi Latest Developments
Table 123. Samsung Bioepis Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 125. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 126. Samsung Bioepis Main Business
Table 127. Samsung Bioepis Latest Developments
Table 128. Teva Pharmaceutical Industries Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 129. Teva Pharmaceutical Industries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 130. Teva Pharmaceutical Industries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 131. Teva Pharmaceutical Industries Main Business
Table 132. Teva Pharmaceutical Industries Latest Developments
Table 133. CANbridge Pharmaceuticals Inc. Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 134. CANbridge Pharmaceuticals Inc. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 135. CANbridge Pharmaceuticals Inc. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 136. CANbridge Pharmaceuticals Inc. Main Business
Table 137. CANbridge Pharmaceuticals Inc. Latest Developments
Table 138. Kira Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 139. Kira Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 140. Kira Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 141. Kira Pharmaceuticals Main Business
Table 142. Kira Pharmaceuticals Latest Developments
Table 143. Wuhan Createrna Science and Technology Co., Ltd. Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 144. Wuhan Createrna Science and Technology Co., Ltd. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 145. Wuhan Createrna Science and Technology Co., Ltd. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 146. Wuhan Createrna Science and Technology Co., Ltd. Main Business
Table 147. Wuhan Createrna Science and Technology Co., Ltd. Latest Developments
Table 148. NovelMed Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 149. NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 150. NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 151. NovelMed Main Business
Table 152. NovelMed Latest Developments
Table 153. Akari Therapeutics Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 154. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 155. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 156. Akari Therapeutics Main Business
Table 157. Akari Therapeutics Latest Developments
Table 158. Omeros Corporation Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 159. Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 160. Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 161. Omeros Corporation Main Business
Table 162. Omeros Corporation Latest Developments
Table 163. Regeneron Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 164. Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 165. Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 166. Regeneron Pharmaceuticals Main Business
Table 167. Regeneron Pharmaceuticals Latest Developments
Table 1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Oral Drugs
Table 4. Major Players of Injectable Drugs
Table 5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021-2026) & (K Doses)
Table 6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Type (2021-2026)
Table 7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Type (2021-2026) & ($ million)
Table 8. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Type (2021-2026)
Table 9. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Type (2021-2026) & (US$/Dose)
Table 10. Major Players of C5 Inhibitors
Table 11. Major Players of C3 Inhibitors
Table 12. Major Players of Other
Table 13. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Complement Target (2021-2026) & (K Doses)
Table 14. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Complement Target (2021-2026)
Table 15. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Complement Target (2021-2026) & ($ million)
Table 16. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Complement Target (2021-2026)
Table 17. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Complement Target (2021-2026) & (US$/Dose)
Table 18. Major Players of Short-Acting: < 2 Weeks
Table 19. Major Players of Medium-Acting: 2?8 Weeks
Table 20. Major Players of Long-Acting: > 8 Weeks
Table 21. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Duration of Action (2021-2026) & (K Doses)
Table 22. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Duration of Action (2021-2026)
Table 23. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Duration of Action (2021-2026) & ($ million)
Table 24. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Duration of Action (2021-2026)
Table 25. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Duration of Action (2021-2026) & (US$/Dose)
Table 26. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale by Application (2021-2026) & (K Doses)
Table 27. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Market Share by Application (2021-2026)
Table 28. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Application (2021-2026) & ($ million)
Table 29. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Application (2021-2026)
Table 30. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Application (2021-2026) & (US$/Dose)
Table 31. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Company (2021-2026) & (K Doses)
Table 32. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Company (2021-2026)
Table 33. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Company (2021-2026) & ($ millions)
Table 34. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Company (2021-2026)
Table 35. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Price by Company (2021-2026) & (US$/Dose)
Table 36. Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Producing Area Distribution and Sales Area
Table 37. Players Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Products Offered
Table 38. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 39. New Products and Potential Entrants
Table 40. Market M&A Activity & Strategy
Table 41. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Geographic Region (2021-2026) & (K Doses)
Table 42. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share Geographic Region (2021-2026)
Table 43. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Geographic Region (2021-2026) & ($ millions)
Table 44. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Geographic Region (2021-2026)
Table 45. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country/Region (2021-2026) & (K Doses)
Table 46. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country/Region (2021-2026)
Table 47. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country/Region (2021-2026) & ($ millions)
Table 48. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Country/Region (2021-2026)
Table 49. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021-2026) & (K Doses)
Table 50. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country (2021-2026)
Table 51. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (2021-2026) & ($ millions)
Table 52. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021-2026) & (K Doses)
Table 53. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2021-2026) & (K Doses)
Table 54. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Region (2021-2026) & (K Doses)
Table 55. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Region (2021-2026)
Table 56. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Region (2021-2026) & ($ millions)
Table 57. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021-2026) & (K Doses)
Table 58. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2021-2026) & (K Doses)
Table 59. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021-2026) & (K Doses)
Table 60. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Country (2021-2026) & ($ millions)
Table 61. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021-2026) & (K Doses)
Table 62. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2021-2026) & (K Doses)
Table 63. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Country (2021-2026) & (K Doses)
Table 64. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Country (2021-2026)
Table 65. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Type (2021-2026) & (K Doses)
Table 66. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Application (2021-2026) & (K Doses)
Table 67. Key Market Drivers & Growth Opportunities of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
Table 68. Key Market Challenges & Risks of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
Table 69. Key Industry Trends of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
Table 70. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Distributors List
Table 73. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Customer List
Table 74. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Forecast by Region (2027-2032) & (K Doses)
Table 75. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Forecast by Region (2027-2032) & ($ millions)
Table 76. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Forecast by Country (2027-2032) & (K Doses)
Table 77. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Forecast by Region (2027-2032) & (K Doses)
Table 79. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 80. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Forecast by Country (2027-2032) & (K Doses)
Table 81. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Forecast by Country (2027-2032) & (K Doses)
Table 83. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Forecast by Type (2027-2032) & (K Doses)
Table 85. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Forecast by Type (2027-2032) & ($ millions)
Table 86. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Forecast by Application (2027-2032) & (K Doses)
Table 87. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Forecast by Application (2027-2032) & ($ millions)
Table 88. AstraZeneca Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 90. AstraZeneca Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 91. AstraZeneca Main Business
Table 92. AstraZeneca Latest Developments
Table 93. Novartis Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 95. Novartis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 96. Novartis Main Business
Table 97. Novartis Latest Developments
Table 98. Apellis Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 100. Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 101. Apellis Pharmaceuticals Main Business
Table 102. Apellis Pharmaceuticals Latest Developments
Table 103. Roche Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 105. Roche Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 106. Roche Main Business
Table 107. Roche Latest Developments
Table 108. Amgen Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 110. Amgen Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 111. Amgen Main Business
Table 112. Amgen Latest Developments
Table 113. Chugai Pharmaceutical Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 115. Chugai Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 116. Chugai Pharmaceutical Main Business
Table 117. Chugai Pharmaceutical Latest Developments
Table 118. Sobi Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Sobi Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 120. Sobi Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 121. Sobi Main Business
Table 122. Sobi Latest Developments
Table 123. Samsung Bioepis Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 125. Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 126. Samsung Bioepis Main Business
Table 127. Samsung Bioepis Latest Developments
Table 128. Teva Pharmaceutical Industries Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 129. Teva Pharmaceutical Industries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 130. Teva Pharmaceutical Industries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 131. Teva Pharmaceutical Industries Main Business
Table 132. Teva Pharmaceutical Industries Latest Developments
Table 133. CANbridge Pharmaceuticals Inc. Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 134. CANbridge Pharmaceuticals Inc. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 135. CANbridge Pharmaceuticals Inc. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 136. CANbridge Pharmaceuticals Inc. Main Business
Table 137. CANbridge Pharmaceuticals Inc. Latest Developments
Table 138. Kira Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 139. Kira Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 140. Kira Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 141. Kira Pharmaceuticals Main Business
Table 142. Kira Pharmaceuticals Latest Developments
Table 143. Wuhan Createrna Science and Technology Co., Ltd. Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 144. Wuhan Createrna Science and Technology Co., Ltd. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 145. Wuhan Createrna Science and Technology Co., Ltd. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 146. Wuhan Createrna Science and Technology Co., Ltd. Main Business
Table 147. Wuhan Createrna Science and Technology Co., Ltd. Latest Developments
Table 148. NovelMed Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 149. NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 150. NovelMed Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 151. NovelMed Main Business
Table 152. NovelMed Latest Developments
Table 153. Akari Therapeutics Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 154. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 155. Akari Therapeutics Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 156. Akari Therapeutics Main Business
Table 157. Akari Therapeutics Latest Developments
Table 158. Omeros Corporation Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 159. Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 160. Omeros Corporation Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 161. Omeros Corporation Main Business
Table 162. Omeros Corporation Latest Developments
Table 163. Regeneron Pharmaceuticals Basic Information, Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 164. Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Product Portfolios and Specifications
Table 165. Regeneron Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales (K Doses), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 166. Regeneron Pharmaceuticals Main Business
Table 167. Regeneron Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
Figure 2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Growth Rate 2021-2032 (K Doses)
Figure 7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country/Region (2025)
Figure 10. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Oral Drugs
Figure 12. Product Picture of Injectable Drugs
Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Type in 2026
Figure 14. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of C5 Inhibitors
Figure 16. Product Picture of C3 Inhibitors
Figure 17. Product Picture of Other
Figure 18. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Complement Target in 2026
Figure 19. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Complement Target (2021-2026)
Figure 20. Product Picture of Short-Acting: < 2 Weeks
Figure 21. Product Picture of Medium-Acting: 2?8 Weeks
Figure 22. Product Picture of Long-Acting: > 8 Weeks
Figure 23. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Duration of Action in 2026
Figure 24. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Duration of Action (2021-2026)
Figure 25. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumed in Pharmaceutical and Biotechnology Companies
Figure 26. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market: Pharmaceutical and Biotechnology Companies (2021-2026) & (K Doses)
Figure 27. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumed in Clinical
Figure 28. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market: Clinical (2021-2026) & (K Doses)
Figure 29. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumed in Others
Figure 30. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market: Others (2021-2026) & (K Doses)
Figure 31. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Market Share by Application (2025)
Figure 32. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Application in 2025
Figure 33. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Company in 2025 (K Doses)
Figure 34. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Company in 2025
Figure 35. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Company in 2025 ($ millions)
Figure 36. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Company in 2025
Figure 37. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 38. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Geographic Region in 2025
Figure 39. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales 2021-2026 (K Doses)
Figure 40. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue 2021-2026 ($ millions)
Figure 41. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales 2021-2026 (K Doses)
Figure 42. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue 2021-2026 ($ millions)
Figure 43. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales 2021-2026 (K Doses)
Figure 44. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue 2021-2026 ($ millions)
Figure 45. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales 2021-2026 (K Doses)
Figure 46. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue 2021-2026 ($ millions)
Figure 47. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country in 2025
Figure 48. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Country (2021-2026)
Figure 49. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Type (2021-2026)
Figure 50. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Application (2021-2026)
Figure 51. United States Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 52. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 53. Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 54. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 55. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Region in 2025
Figure 56. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Region (2021-2026)
Figure 57. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Type (2021-2026)
Figure 58. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Application (2021-2026)
Figure 59. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 60. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 61. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 62. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 63. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 64. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 65. China Taiwan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 66. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country in 2025
Figure 67. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Country (2021-2026)
Figure 68. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Type (2021-2026)
Figure 69. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Application (2021-2026)
Figure 70. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 71. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 72. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 73. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 74. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 75. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country (2021-2026)
Figure 76. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Type (2021-2026)
Figure 77. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Application (2021-2026)
Figure 78. Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 79. South Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 80. Israel Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 81. Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 82. GCC Countries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 83. Manufacturing Cost Structure Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs in 2026
Figure 84. Manufacturing Process Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
Figure 85. Industry Chain Structure of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
Figure 86. Channels of Distribution
Figure 87. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Forecast by Region (2027-2032)
Figure 88. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 89. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 90. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 91. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 92. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
Figure 2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Growth Rate 2021-2032 (K Doses)
Figure 7. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country/Region (2025)
Figure 10. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Oral Drugs
Figure 12. Product Picture of Injectable Drugs
Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Type in 2026
Figure 14. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of C5 Inhibitors
Figure 16. Product Picture of C3 Inhibitors
Figure 17. Product Picture of Other
Figure 18. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Complement Target in 2026
Figure 19. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Complement Target (2021-2026)
Figure 20. Product Picture of Short-Acting: < 2 Weeks
Figure 21. Product Picture of Medium-Acting: 2?8 Weeks
Figure 22. Product Picture of Long-Acting: > 8 Weeks
Figure 23. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Duration of Action in 2026
Figure 24. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Duration of Action (2021-2026)
Figure 25. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumed in Pharmaceutical and Biotechnology Companies
Figure 26. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market: Pharmaceutical and Biotechnology Companies (2021-2026) & (K Doses)
Figure 27. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumed in Clinical
Figure 28. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market: Clinical (2021-2026) & (K Doses)
Figure 29. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Consumed in Others
Figure 30. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Market: Others (2021-2026) & (K Doses)
Figure 31. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sale Market Share by Application (2025)
Figure 32. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Application in 2025
Figure 33. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales by Company in 2025 (K Doses)
Figure 34. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Company in 2025
Figure 35. Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue by Company in 2025 ($ millions)
Figure 36. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Company in 2025
Figure 37. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Geographic Region (2021-2026)
Figure 38. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Geographic Region in 2025
Figure 39. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales 2021-2026 (K Doses)
Figure 40. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue 2021-2026 ($ millions)
Figure 41. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales 2021-2026 (K Doses)
Figure 42. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue 2021-2026 ($ millions)
Figure 43. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales 2021-2026 (K Doses)
Figure 44. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue 2021-2026 ($ millions)
Figure 45. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales 2021-2026 (K Doses)
Figure 46. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue 2021-2026 ($ millions)
Figure 47. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country in 2025
Figure 48. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Country (2021-2026)
Figure 49. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Type (2021-2026)
Figure 50. Americas Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Application (2021-2026)
Figure 51. United States Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 52. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 53. Mexico Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 54. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 55. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Region in 2025
Figure 56. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Region (2021-2026)
Figure 57. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Type (2021-2026)
Figure 58. APAC Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Application (2021-2026)
Figure 59. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 60. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 61. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 62. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 63. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 64. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 65. China Taiwan Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 66. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country in 2025
Figure 67. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share by Country (2021-2026)
Figure 68. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Type (2021-2026)
Figure 69. Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Application (2021-2026)
Figure 70. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 71. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 72. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 73. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 74. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 75. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Country (2021-2026)
Figure 76. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Type (2021-2026)
Figure 77. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share by Application (2021-2026)
Figure 78. Egypt Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 79. South Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 80. Israel Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 81. Turkey Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 82. GCC Countries Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Growth 2021-2026 ($ millions)
Figure 83. Manufacturing Cost Structure Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs in 2026
Figure 84. Manufacturing Process Analysis of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
Figure 85. Industry Chain Structure of Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
Figure 86. Channels of Distribution
Figure 87. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Forecast by Region (2027-2032)
Figure 88. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share Forecast by Region (2027-2032)
Figure 89. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share Forecast by Type (2027-2032)
Figure 90. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share Forecast by Type (2027-2032)
Figure 91. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Sales Market Share Forecast by Application (2027-2032)
Figure 92. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs Revenue Market Share Forecast by Application (2027-2032)
